

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**In re application of:** John Joseph Deadman et al.

**Application No.:** 10/659,179

**Filed:** September 9, 2003

**Confirmation No.:** 7468

**For:** MULTIVALENT METAL SALTS OF  
BORONIC ACIDS

**Examiner:** Marcela M. Cordero Garcia

**Art Unit:** 1654

**Attorney Reference No.:** 6613-66764-01

**CERTIFICATE OF EXPRESS MAILING**

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as Express Mail Label No. EV669611839US in an envelope addressed to: MAIL STOP AMENDMENT, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney or Agent  
for Applicant(s) *Myra R. Russell*

Date Mailed November 21, 2005

MAIL STOP AMENDMENT  
COMMISSIONER FOR PATENTS  
P.O. BOX 1450  
ALEXANDRIA, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**  
**PURSUANT TO 37 C.F.R. § 1.97(c)**

Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language documents. Applicants respectfully request that these documents be listed as references cited on the issued patent. This Information Disclosure Statement ("IDS") is being mailed before Applicants received a final action, a notice of allowance, or an action that otherwise closes prosecution in the referenced application.

Submitted herewith is a check for \$180.00 as required by 37 C.F.R. § 1.17(p) for filing this IDS in compliance with 1.97(c).

Please charge any additional fees which may be required in connection with filing this IDS, or credit any overpayment, to Deposit Account No. 02-4550. A duplicate copy of this sheet is enclosed.

11/28/2005 WABDELRL1 00000008 10659179


03 FC:1806

180.00 OP


The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By   
Wayne W. Rupert  
Registration No. 34,420

One World Trade Center, Suite 1600  
121 S.W. Salmon Street  
Portland, Oregon 97204  
Telephone: (503) 595-5300  
Facsimile: (503) 228-9446

<b>INFORMATION DISCLOSURE STATEMENT</b> <b>BY APPLICANT</b> 	Attorney Docket Number	6613-66764-01
	Application Number	10/659,179
	Filing Date	September 9, 2003
	First Named Inventor	John Joseph Deadman
	Art Unit	1654
	Examiner Name	Marcela M. Cordero Garcia

### U.S. PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee
		5,169,841	08 Dec 1992	Kleeman et al.
		5,639,739	17 June 1997	Dominguez et al.
		6,114,308	05 Sept 2000	Claeson et al.
		6,297,217	02 Oct 2001	Adams et al.
		6,417,174	09 July 2002	Shoichet et al.
		US-2005-0119226 A1	02 June 2005	Walter et al.
		US-2005-0176651 A1	11 Aug 2005	Madge

### FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee
		Europe	EP 0 235 692	19 Feb 1987	Behringwerke Aktiengesellschaft
		Europe	EP 0 599 633	24 Nov 1993	Thrombosis Research Institute
		WIPO/PCT	WO 89/09612	19 Oct 1989	Corvas, Inc.
		WIPO/PCT	WO 94/21668	29 Sept 1994	The DuPont Merck Pharmaceutical Company
		WIPO/PCT	WO 98/00443	08 Jan 1998	Thrombosis Research Institute

EXAMINER SIGNATURE:	DATE CONSIDERED:
* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.	

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Attorney Docket Number	6613-66764-01
		Application Number	10/659,179
		Filing Date	September 9, 2003
		First Named Inventor	John Joseph Deadman
		Art Unit	1654
		Examiner Name	Marcela M. Cordero Garcia
Examiner's Initials*	Cite No. (optional)	<b>OTHER DOCUMENTS</b>	
		Bastin et al., "Salt Selection and Optimisation Procedures for Pharmaceutical New Chemical Entities," <i>Organic Process Research &amp; Development</i> 4:427-435, 2000	
		Berge et al., "Pharmaceutical Salts," <i>Journal of Pharmaceutical Sciences</i> 66(1):1-19, 1977	
		Brikh et al., "Boronated thiophenols: a preparation of 4-mercaptophenylboronic acid and derivatives," <i>Journal of Organometallic Chemistry</i> 581:82-86, 1999	
		Davies et al., "Peroxides of Elements other than Carbon. Part XII. The Autoxidation of Optically Active 1-Phenylethylboronic Acid," <i>J Chem Soc</i> pp. 17-22, 1967	
		Elgendy et al., "Design of a novel class of bifunctional thrombin inhibitors, synthesised by the first application of peptide boronates of solid phase chemistry," <i>Tetrahedron Letters</i> 38(18):3305-3308, 1997	
		Hsiao et al., "A Facile Synthesis of <i>tert</i> -Butyl 2-[Benzyloxycarbonyl]amino]-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propionate: An Orthogonally Protected Boronic Acid Analog of Aspartic Acid," <i>Synthesis</i> 7:1043-1046, 1998	
		Kettner et al., "Inhibition of the Serine Proteases Leukocyte Elastase, Pancreatic Elastase, Cathepsin G, and Chymotrypsin by Peptide Boronic Acids," <i>The Journal of Biological Chemistry</i> 259(24):15106-15114, 1984	
		Kettner et al., "The Selective Inhibition of Thrombin of Peptides of Boroarginine," <i>The Journal of Biological Chemistry</i> 265(30):18289-18297, 1990	
		Lappert, "Organic Compounds of Boron," <i>Chem. Review</i> 56:959-1064, 1956	
		Martichonok et al., "Cysteine Proteases such as Papain are not Inhibited by Substrate Analogue Peptidyl Boronic Acids," <i>Bioorganic and Medicinal Chemistry</i> 5(4):679-684, 1997	
		Snyder et al., "Organoboron Compounds, and the Study of Reaction Mechanisms. Primary Aliphatic Boronic Acids," <i>Am Chem Soc</i> 60:105-111, 1938	
		Snyder et al., "Aryl Boronic Acids. II. Aryl Boronic Anhydrides and their Amine Complexes," <i>Am Chem Soc</i> 80:3611-3615, 1958	
		Wityak et al., "Synthesis of Thrombin Inhibitor DuP 714," <i>J. Org. Chem.</i> 60:3717-3722, 1995	

EXAMINER SIGNATURE:	DATE CONSIDERED:
<p>* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	